Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Eur J Gynaecol Oncol ; 38(2): 319-322, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-29953805

RESUMO

Mixed endometrial stromal and smooth muscle tumor of the uterus is a rare occurrence, and it is truly challenging to diagnose or dif- ferentiate mesenchymal tumors of the uterine corpus, due to their many overlapping features. In most cases, the gross pathology of mixed endometrial stromal and smooth muscle tumor differs from that of pure endometrial stromal and pure smooth muscle tumors. A 59-year-old postmenopausal woman presented with vaginal spotting, low abdominal pain, and an uterine mass. Subsequent pelvic magnetic resonance imaging revealed a 4.0x3.8x3.4-cm sized uterine mass with enhancement. The mass showed restricted diffusion on diffusion-weighted images, and thus, was suspected to be uterine sarcoma rather than degenerative leiomyoma. Levels of tumor markers, CA 125, CA 19-9, and SCC, were within their normal ranges. The patient underwent exploratory laparotomy. Morphological and immunohistochemical evaluations were performed, and a final diagnosis of mixed endometrial stromal and smooth muscle tumor of the uterus was rendered. Her postoperative course was uneventful, and aromatase inhibitor adjuvant therapy was administered.


Assuntos
Neoplasias do Endométrio/patologia , Tumores do Estroma Endometrial/patologia , Neoplasias Complexas Mistas/patologia , Tumor de Músculo Liso/patologia , Desmina/metabolismo , Neoplasias do Endométrio/metabolismo , Tumores do Estroma Endometrial/metabolismo , Feminino , Humanos , Pessoa de Meia-Idade , Neoplasias Complexas Mistas/metabolismo , Neprilisina/metabolismo , Tumor de Músculo Liso/metabolismo
2.
Clin Radiol ; 68(2): 117-24, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22795944

RESUMO

AIM: To differentiate remnant tumour from postoperative changes on short-term follow-up magnetic resonance imaging (MRI) or combined positron-emission tomography (PET) and computed tomography (CT) after inadequate primary resection of malignant soft-tissue tumours. MATERIALS AND METHODS: From January 2007 through September 2010, 35 patients (18 women and 17 men; mean age 48 years; age range 18-78 years) who underwent MRI and PET-CT within 64 days after surgery for malignant soft-tissue tumours were included. MRI images were assessed for the following findings: the presence of delineated enhancing portions; fascial thickening; and fluid or haematomas with measurable wall thickening. The PET-CT data were analysed using the standardized uptake value (SUV) and the uptake pattern. RESULTS: The correlation of tumour grade and the presence of remnant tumour was significant (p = 0.026). After re-excision, remnant tumour was demonstrated in 15 patients and no tumour cells were discovered in 20 patients. The finding of focally delineated enhancing portions on MRI images and the SUVmax on PET-CT analysis were significantly correlated with the remnant tumour (each p = 0.001 and p = 0.036). CONCLUSIONS: To evaluate the presence of remnant tumour after inadequate excision of malignant soft-tissue tumours, an MRI finding of a focally enhancing area and an SUVmax of >2 on PET-CT might be helpful factors. The coexistence of these two findings would be even more helpful for the detection of residual tumours.


Assuntos
Imageamento por Ressonância Magnética/métodos , Imagem Multimodal/métodos , Neoplasia Residual/diagnóstico , Tomografia por Emissão de Pósitrons , Neoplasias de Tecidos Moles/diagnóstico , Neoplasias de Tecidos Moles/cirurgia , Tomografia Computadorizada por Raios X , Adolescente , Adulto , Idoso , Distribuição de Qui-Quadrado , Estudos de Coortes , Estudos de Avaliação como Assunto , Feminino , Seguimentos , Humanos , Interpretação de Imagem Assistida por Computador , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Estudos Retrospectivos , Medição de Risco , Neoplasias de Tecidos Moles/patologia , Análise de Sobrevida , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
3.
Acta Anaesthesiol Scand ; 54(7): 885-93, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20039844

RESUMO

BACKGROUND: Sevoflurane is a widely used inhalation anesthetic, but there are no studies on its effect on the wound-healing process. This study was undertaken to evaluate the effect of exposure time to sevoflurane on wound healing. METHOD: Male Sprague-Dawley rats were used. Two circular full-thickness skin defects 8 mm in diameter were made on the dorsum of the rats. The animals were divided into six groups according to exposed gas type and time: S1 (sevoflurane, 1 h), S4 (sevoflurane, 4 h), S8 (sevoflurane, 8 h), O1 (oxygen, 1 h), O4 (oxygen, 4 h), and O8 (oxygen, 8 h). The surface area of the wounds was measured 0, 1, 3, and 7 days after surgery. Separately, the mean blood pressures (MBP) and arterial oxygen pressures (PaO(2)) were monitored during the sevoflurane exposure. Collagen type I production and transforming growth factor-beta1 (TGF-beta1) and basic fibroblast growth factor (bFGF) expression on the wound surface were analyzed. Routine histological analysis was also performed. RESULT: Exposure duration to sevoflurane had no influence on MBP and PaO(2). The reduction in wound size and collagen type I production was delayed in S8. The expression of TGF-beta1 and bFGF on the wound surface in S8 was significantly attenuated in S8. The histology of the S8 demonstrated a delayed healing status. CONCLUSIONS: Prolonged exposure to sevoflurane might alter the inflammatory phase of the wound-healing process by attenuation of growth factor expression such as TGF-beta1 and bFGF and subsequently by reduced collagen production.


Assuntos
Anestésicos Inalatórios/farmacologia , Colágeno/biossíntese , Peptídeos e Proteínas de Sinalização Intercelular/biossíntese , Éteres Metílicos/farmacologia , Cicatrização/efeitos dos fármacos , Ferimentos e Lesões/metabolismo , Animais , Pressão Sanguínea/efeitos dos fármacos , Western Blotting , Fator 2 de Crescimento de Fibroblastos/biossíntese , Imuno-Histoquímica , Masculino , Oxigênio/sangue , RNA/biossíntese , RNA/isolamento & purificação , Ratos , Ratos Sprague-Dawley , Sevoflurano , Fator de Crescimento Transformador beta1/biossíntese , Ferimentos e Lesões/patologia
4.
Clin Radiol ; 63(11): 1236-44, 2008 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18929041

RESUMO

AIM: To evaluate the association between computed tomography (CT) detection of early gastric cancer (EGC) and various parameters, including the depth of invasion, lesion extent, morpholgical type, location, and histological type. MATERIALS AND METHODS: One hundred and ten patients with 114 EGCs were preoperatively examined using multidetector CT (MDCT). All patients received 500 ml water as an oral contrast agent approximately 15 min before the examination and an additional 500 ml immediately prior to the study. Portal venous phase, contrast-enhanced, helical scans with multiplanar reformation were obtained. All patients underwent surgery. For location and size of tumour, the CT findings were compared with the histopathological results. The association between CT detection of EGC and various parameters were assessed. In addition, we performed a stepwise forward logistic regression to identify which variables significantly increased the CT detection rate of EGC. RESULTS: The detection rate of all EGCs using MDCT was 36.4%. The detection rate for EGCs confined to the superficial layer (mucosa or SM1) was 14.3%, whereas the detection rate for EGCs that involved the deep layer (SM2 or more than SM2) was 86.5%. All three of the protruded lesions and five of the six excavated lesions were readily detected using CT. Stepwise forward logistic regression showed that the best parameter for CT detection of EGCs was the depth of invasion; more EGCs were detected when the lesion was deep. CONCLUSION: MDCT has advantages in acceptable evaluation of the depth invasion of EGCs. EGC that is undetectable using CT suggests an EGC confined to the superficial layer, whereas EGC detectable using CT suggests deep lesions.


Assuntos
Neoplasias Gástricas/diagnóstico por imagem , Neoplasias Gástricas/patologia , Adulto , Idoso , Artefatos , Diagnóstico Precoce , Feminino , Mucosa Gástrica/patologia , Gastroscopia , Humanos , Interpretação de Imagem Assistida por Computador/métodos , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Estudos Retrospectivos , Tomografia Computadorizada por Raios X
5.
Int J Gynecol Cancer ; 18(3): 492-8, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-17692085

RESUMO

E2F-1 is a downstream regulator of the Rb pathway and is a transcription factor that plays a key role in the control of cell cycle progression. Deregulation of E2F-1 expression and Rb pathway is involved in carcinogenesis. The aim of this study was to evaluate E2F-1 expression and Rb pathway alteration and to elucidate their correlation with clinical and pathologic parameters in epithelial ovarian cancer (EOC). We investigated overexpression of E2F-1 and alterations of p16(INK4a), cyclin D1, CDK4, and pRb using immunohistochemistry and tissue microarray methods in 72 EOC patients. Overexpression of E2F-1 was detected in 45.8% of samples. The overall abnormal expression frequencies of p16(INK4a), cyclin D1, CDK4, and pRb were 33.3%, 11.1%, 12.5%, and 38.9%, respectively. E2F-1 overexpression was not associated with alteration of the Rb pathway. E2F-1 overexpression was correlated with FIGO stage, histologic grade, and mitotic index; it was a valuable prognostic variable along with FIGO stage in the multivariated analysis. The results suggest that E2F-1 has a growth-promoting effect in EOC and that E2F-1 overexpression may provide a useful prognostic indicator for EOC.


Assuntos
Fator de Transcrição E2F1/genética , Regulação Neoplásica da Expressão Gênica , Predisposição Genética para Doença , Neoplasias Epiteliais e Glandulares/genética , Neoplasias Ovarianas/genética , Distribuição de Qui-Quadrado , Intervalos de Confiança , Ciclina D1/genética , Ciclina D1/metabolismo , Quinase 4 Dependente de Ciclina/genética , Quinase 4 Dependente de Ciclina/metabolismo , Fator de Transcrição E2F1/metabolismo , Feminino , Humanos , Imuno-Histoquímica , Estimativa de Kaplan-Meier , Análise Multivariada , Neoplasias Epiteliais e Glandulares/mortalidade , Neoplasias Epiteliais e Glandulares/patologia , Neoplasias Ovarianas/mortalidade , Neoplasias Ovarianas/patologia , Probabilidade , Prognóstico , Estudos Retrospectivos , Medição de Risco , Sensibilidade e Especificidade , Análise de Sobrevida , Técnicas de Cultura de Tecidos
6.
Histol Histopathol ; 20(2): 543-9, 2005 04.
Artigo em Inglês | MEDLINE | ID: mdl-15736060

RESUMO

Smads are signal transducers for the members of the TGF-beta superfamily. Of these Smads, Smad4 is essential for TGF-beta signaling. The purpose of this study was to elucidate Smad4 expression and localization in 65 gastric adenomas, 49 intestinal-type and 39 diffuse type of gastric adenocarcinomas (including 12 cases of fresh frozen tissue) using Real-time RT-PCR and immunohistochemistry. Real-time RT-PCR showed that intestinal type gastric adenocarcinomas have higher Smad4 mRNA expression than diffuse type gastric adenocarcinomas. Immunohistochemical stain for Smad4 revealed that expression of Smad4 was significantly lower in diffuse-type gastric adenocarcinoma than intestinal-type gastric adenocarcinomas. Also, higher Smad4 protein expression in intestinal type gastric adenocarcinomas than overall gastric adenoma was noted. The rate of reduced Smad4 expression was higher in advanced gastric cancer than early gastric cancer. These results suggest that Smad4 might play different roles in human gastric carcinogenesis, especially between intestinal type and diffuse type of gastric adenocarcinoma.


Assuntos
Adenocarcinoma/genética , Adenocarcinoma/metabolismo , Adenoma/genética , Adenoma/metabolismo , Proteínas de Ligação a DNA/genética , Proteínas de Ligação a DNA/metabolismo , Neoplasias Gástricas/genética , Neoplasias Gástricas/metabolismo , Transativadores/genética , Transativadores/metabolismo , Adenocarcinoma/patologia , Adenoma/patologia , Adulto , Idoso , Sequência de Bases , Feminino , Mucosa Gástrica/metabolismo , Expressão Gênica , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , RNA Neoplásico/genética , RNA Neoplásico/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transdução de Sinais , Proteína Smad4 , Neoplasias Gástricas/patologia , Fator de Crescimento Transformador beta/metabolismo
7.
Arch Pharm Res ; 24(5): 390-6, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11693537

RESUMO

Synthesized 6-arylamino-5,8-quinolinediones 4a-4j and 6-chloro-7-arylamino-5,8-isoquinolinediones 5a-5g were evaluated for effects on NAD(P)H: quinone oxidoreductase (NQO1) activity with the cytosolic fractions derived from cultured human lung cancer cells and their cytotoxicity in cultured several human solid cancer cell lines. The 5,8-quinolinediones 4 and 5,8-isoquinolinediones 5 affected the reduction potential by NQO1 activity and showed a potent cytotoxic activity against human cancer cell lines. The tested compounds 4a, 5c, 5f, and 5g were considered as more potent cytotoxic agents. The compounds 4d, 5b, 5c, 5e and 5g were comparable modulators of NQO1 activity.


Assuntos
Antineoplásicos/síntese química , Antineoplásicos/farmacologia , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacologia , NAD(P)H Desidrogenase (Quinona)/antagonistas & inibidores , Quinolonas/síntese química , Quinolonas/farmacologia , Quinonas/síntese química , Quinonas/farmacologia , Sobrevivência Celular/efeitos dos fármacos , Humanos , Indicadores e Reagentes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...